Currently set to Index
Currently set to Follow
search
ask age2b
CART 0

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

By AGE2B team
April 12, 2021
0
0

Mark L Hartman 1, Arun J Sanyal 2, Rohit Loomba 3 4, Jonathan M Wilson 5, Amir Nikooienejad 5, Ross Bray 5, Chrisanthi A Karanikas 5, Kevin L Duffin 5, Deborah A Robins 5, Axel Haupt 5

Main idea: In post hoc analyses, higher tirzepatide doses significantly decreased NASH-related biomarkers and increased adiponectin in patients with T2DM.

Abstract

Objective: To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with type 2 diabetes mellitus (T2DM).

Research design and methods: We retrieved 37 trials, including 3301 patients. Average carbohydrate intake in LC diets was 36% of total energy. VLC diets were associated with significant HbA1c reduction at 3 and 6 months, but not at 12 and 24 months. No significant differences in body weight, lipid profile, or blood pressure were found in the long term. Only a minority of trials reported data on renal function, so renal safety could not be assessed. 

Results: Significant reductions from baseline in ALT (all groups), AST, and AST were observed at 26 weeks. Decreases with tirzepatide were significant compared with placebo for K-18 (10 mg) and Pro-C3 (15 mg) Adiponectin significantly increased from baseline with Tirzep atide compared to placebo.

Source NIH

Leave a Reply

Ask your question

We read all your emails and your text. Your question will be responded by our specialists, or one of the doctors we're working with, or our community

Please complete the required fields.